Anyhow, we are very underexposed to healthcare since we like 20%+ type of growth and only so many companies can provide it. We've had a few ventures with Myriad Genetics (MYGN) the past 2.5 years, some successful - some not. The stock has just broken out from below some resistance areas so I am going to give it another shot, with a 2% allocation around $25.60. We last closed out a position in Myriad in early November about a dollar lower than this level - so we have not missed much.
[click to enlarge]
The stock has bow broken over the 50 day moving average after going sideways for much of the past 2 months, we'll use the 20 and 50 days as new support levels / stop out levels. If it can continue to move, it should have relatively clear sailing until running into the 200 day moving average up near $28 (and falling)
With earnings of $1.45 (est.) for year end Jun 2010, the forward PE is under 20, for a 20% type of grower. The stock has simply been in the doghouse for much of 2009, unlike its superstar status in 2008. Hopefully ti can catch some mojo in 2010.
Long Myriad Genetics in fund; no personal position